COMMUNICATION
Characterization of the Human Analogue of a Scrapie-responsive Gene*

Michel DronDagger , Françoise Dandoy-DronDagger , Frédéric GuilloDagger , Louisa BenboudjemaDagger §, Jean-Jacques Hauw, Pierre Lebonparallel , Dominique Dormont**, and Michael G. ToveyDagger Dagger Dagger

From the Dagger  Laboratory of Viral Oncology CNRS UPR 9045, IFC1, 94801 Villejuif cedex, France, the  Laboratoire de Neuropathologie Raymond Escourolle, Groupe Hospitalier Pitié-Salpêtrière, INSERM U360, Association Claude Bernard, 75651 Paris cedex 13, France, the parallel  Laboratoire de Virologie, Hôpital Saint Vincent de Paul, 75674 Paris cedex 14, France, and the ** Laboratoire de Neurovirologie CEA, 92265 Fontenay aux Roses cedex, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

We have recently described a novel mRNA denominated ScRG-1, the level of which is increased in the brains of Scrapie-infected mice (Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.-P., Lasmézas, C., Dormont, D., Tovey, M. G., and Dron, M. (1998) J. Biol. Chem. 273, 7691-7697). The increase in ScRG-1 mRNA in the brain follows the accumulation of PrPSc, the proteinase K-resistant form of the prion protein (PrP), and precedes the widespread neuronal death that occurs in late stage disease. In the present study, we have isolated a cDNA encoding the human counterpart of ScRG-1. Comparison of the human and mouse transcripts firmly established that both sequences encode a highly conserved protein of 98 amino acids that contains a signal peptide, suggesting that the protein may be secreted. Examination of the distribution of human ScRG-1 mRNA in adult and fetal tissues revealed that the gene was expressed primarily in the central nervous system as a 0.7-kilobase message and was under strict developmental control.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

The transmissible spongiform encephalopathies (TSE)1 are in a group of progressive neurodegenerative diseases that includes human pathologies such as Creutzfeldt-Jakob disease (CJD), Gerstman-Sträussler-Scheinker syndrome and Kuru, and animal diseases such as scrapie and bovine spongiform encephalopathy (1).

To identify the genes the altered expression of which is associated with or may even be responsible for the neurodegenerative changes observed in TSE, we have systematically analyzed modifications of gene expression in scrapie-infected mouse brain using "mRNA differential display" (2). This approach has led to the detection of an increased level of expression of eight cellular genes. One of these genes, denominated scrapie-responsive gene 1 (ScRG-1), previously unrecognized, is expressed principally in the brain. Enhanced expression of ScRG-1 in the brain of scrapie-infected mice occurs concomitantly with increased expression of GFAP mRNA, a marker of astrocytosis (3). Moreover, ScRG-1 mRNA was found to be preferentially expressed in cells of glial origin and to encode a protein with a putative signal peptide (2). These observations suggest that ScRG-1 may play a role in the host response to prion-associated infections. Previous reports have suggested that certain molecules enhanced in TSE may be detrimental to neurone survival (4-6). However, the role of overexpressed proteins (7-9), including ScRG-1, in the pathogenesis of TSE remains to be determined. We report herein the nucleotide sequence, size characterization, and tissue distribution of human ScRG-1 mRNA.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

RNA Extraction and Northern Blot Hybridization-- RNA was extracted from the brains of either mock infected C57Bl/6 mice or mice infected with the C506M3 strain of scrapie, as described previously (2). Total RNA was extracted by the method of Chirgwin et al. (10) from the frontal cortex obtained at autopsy from a patient free from any neurological disease (patient 941005, 46 years old) and from a patient with typical neuropathological findings of sporadic Creutzfeldt-Jakob disease (patient 93005, 59 years old). The diagnosis was confirmed by the presence of the proteinase K-resistant form of PrP in the sample (data not shown). Samples of normal human brain and of the brain from a patient diagnosed with CJD were obtained by informed consent, under the auspices of the Program de Recherche sur les Encéphalopathies Spongiformes Sub-aigües Transmissibles et les Prions (CNRS, France). Human poly(A)+ mRNA was obtained as described previously (2). Northern blots were performed using glyoxal denaturation, and the blotted membranes were hybridized using probes radiolabeled to a specific activity of at least 1 × 109 cpm/mg, as described previously (2). The blots were first exposed to autoradiography and then quantified using a PhosphorImager (Molecular Dynamics). The multiple human tissue Northern blot and the membrane containing the RNA dots from different human tissues were from CLONTECH laboratories.

Cloning and Sequencing of the Human cDNA-- 1 µg of poly(A)+ mRNA from the human control sample was primed with oligo(dT) and converted into double strand cDNA using standard procedures. One-twentieth of the cDNA synthesized was amplified by polymerase chain reaction using specific forward (5'-TAAGGGAAAATCACGCTGTG-3') and reverse (5'-CTTTTATTACTACTTGTTTAACAC-3') primers and Taq DNA polymerase. The amplified product was purified, sequenced using the Thermo Sequenase cycle sequencing kit (Amersham Pharmacia Biotech), and further cloned in the pCR2.1 Topo plasmid vector from Invitrogen.

Cloning and Sequencing of Mouse ScRG-1 cDNA-- Mouse ScRG-1 cDNA was isolated by screening a library of whole BALB/c adult brain cDNA cloned in lambda gt11, with the ScRG-1 cDNA clone 24 previously isolated by RACE (2) used as a probe. The cDNA inserted in the selected lambda (clone 1) was isolated and further sequenced.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Isolation of Human ScRG-1 cDNA-- To isolate the human counterpart of the mouse ScRG-1 cDNA, the murine sequence (2) was compared with the randomly isolated human cDNA sequences reported as expressed sequence tags. The sequences potentially related to the mouse cDNA were combined in a contig and used to establish a human consensus sequence corresponding to a putative 902-bp cDNA. To ascertain the existence of the human ScRG-1 mRNA, primers derived from the 5' and 3' ends of the consensus sequence were used to synthesize cDNA from human brain mRNA by specific reverse transcription and polymerase chain reaction amplification. An unique cDNA fragment of the predicted size was obtained, cloned, and sequenced (Fig. 1A). Mapping using expressed sequence tag cDNA related to ScRG-1 indicated that the human gene was located on the long arm of chromosome four (4q31-4q32).


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 1.   Comparison of the human and murine ScRG-1 nucleotide sequences. The nucleic acid sequences (A) of the human and murine ScRG-1 cDNAs were aligned for comparison. The beginning of the human cDNA sequence amplified from the brain of patient 941005 is indicated by an arrow. Position 1 of the mouse sequence is the 5' end of the longest brain cDNA obtained by 5'-RACE (2). Most of the mouse cDNAs obtained previously were shorter than the clone 24 cDNA, and their 5' ends start at a position between 143 and 148. The mouse cDNA clone 1, isolated from the lambda cDNA library starts also at position 148, indicated by an arrow. The coding sequences of both the human and murine cDNA as well as the two potential polyadenylation sites were underlined or overlined. The translation products of the human and murine coding sequences (B) were aligned without introduction of any gap in the sequence. For both sequences the first 20 amino acids corresponding to a potential cleavable signal peptide were underlined.

The sequence of the human cDNA was compared with the 700-bp murine ScRG-1 cDNA. The two sequences were found to be very similar with an homology of 75.8% in an overlap of 720 nucleotides (Fig. 1A). The human cDNA contained an open reading frame (ORF) at positions 414-710 encoding a protein exhibiting strong homology with the protein predicted from the murine ScRG-1 cDNA (Fig. 1B).

The human ORF was found to encode a protein of 98 amino acids, which is 51 amino acids more than previously predicted for the murine protein (2). Comparison of human and murine cDNA sequences indicated that introduction of a one-nucleotide gap in the murine ORF would generate an open reading frame corresponding to a protein of 98 amino acids the sequence of which would be almost identical to that encoded by the human ScRG-1 cDNA. This prompted us to clone a new mouse brain ScRG-1 cDNA from a lambda library, using as a probe the ScRG-1 cDNA clone 24 previously isolated by RACE (2). The sequence of clone 1 obtained from the library was then determined (Fig. 1A). The nucleotide sequences of the different cDNAs previously obtained by RACE (2) were also re-examined. The mouse ORF, which was reported to contain two guanosines at positions 345 and 346, was found in fact to contain three guanosines at positions 345, 346, and 347, immediately following a sequence consisting of a succession of nucleotides repeated twice, thereby constructing an imperfect palindrome. The additional guanosine signal (position 345) was very weak in intensity and abnormally close to the following nucleotide. The presence of the "missing G" was confirmed by sequencing a recently isolated murine genomic DNA clone of ScRG-1 (data not shown). The corrected nucleotide sequence of the mouse brain ScRG-1 cDNA and derived amino acid sequence (Fig. 1, A and B) have been reported in the data bases.

Comparison of the human and mouse ScRG-1 coding sequences showed that 82.5% of the amino acids of the two predicted proteins are identical, with a stretch of 40 identical contiguous amino acids in the carboxyl-terminal region of the protein (Fig. 1B). The ScRG-1 proteins exhibit no apparent homology with other known proteins. Both the human and murine proteins contain a cleavable signal peptide of 20 amino acids in length. Furthermore, the probability that ScRG-1 is external to the plasma membrane is 56% for the murine protein and 48% for human protein according to the PSORT II program of protein localization site prediction. The predicted molecular mass of the mature protein for the two species is approximately 9 kDa, which is in the range of the molecular weight of most cytokines and neurotransmitters. A N-glycosylation site was detected at positions 72-75 of the protein for both species so that the molecular weight of the ScRG-1 protein could be substantially higher in vivo. A tyrosine kinase phosphorylation site was also detected at positions 63-70 in both proteins.

Characterization of Human Brain ScRG-1 mRNA-- Northern blot analysis was carried out using RNA from both human and mouse brain to determine the size of the transcripts in the two species. 14 individual RNA species were used as molecular weight markers. The blot was split in two parts to separate the mouse and human samples, and each part was hybridized under stringent conditions with a radiolabeled probe derived from murine and human ScRG-1 cDNA, respectively (Fig. 2, A and B). One band corresponding to 0.7 kb in size was detected in the human samples and as expected, two bands of 2.6 and 0.7 kb were detected in the murine samples. A very faint band of 2.6 kb was also revealed upon overexposure of the autoradiograms of the human blot (data not shown). The faster migrating band was relatively broad, with an estimated size of between 0.66 and 0.82 kb (mean size of 0.74 kb) in both species. Quantification by PhosphorImager indicated that the 0.7-kb message represented at least 75-80% of the ScRG-1 transcripts in murine brain and about 98% of the transcripts in human brain. The relative abundance of the ScRG-1 mRNA in this organ was about 40 times less than the level of beta -actin mRNA in both species.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   Northern blot analysis of human and mouse ScRG-1 mRNA. A Northern blot containing 2 µg of poly(A)+ RNA from the frontal cortex of patient 941005 (normal) and patient 930005 (CJD) (A) were transferred to a membrane that was hybridized under stringent conditions with radiolabeled human ScRG-1 cDNA. The blot was further dehybridized and rehybridized successively with probes derived from cDNA of the human cathepsin S, hamster GFAP, and murine beta -actin. Similarly, a Northern blot (B) containing 10 µg of total brain RNA from C57Bl/6 mice, mock infected or infected with the C506M3 strain of scrapie and sacrificed 170 days post inoculation, was hybridized with the murine ScRG-1 cDNA clone 24 isolated by RACE (2). The third part of figure (C) shows the autoradiogram of a membrane containing 2 µg of poly(A)+ mRNA from different adult human tissues, probed with the human ScRG-1 cDNA. The different ScRG-1 transcripts shown in the three panels are indicated by arrows, and the corresponding sizes are stated.

We have reported previously that the 0.7-kb ScRG-1 transcript is overexpressed 2-3-fold in scrapie-infected mouse brain (Ref. 2 and Fig. 2). As shown in Fig. 2B, the level of the 2.6-kb transcript is also increased 2-3-fold in this experimental model of TSE disease. It was of interest to determine whether the level of human ScRG-1 mRNA is increased in samples of brain from patients with CJD. Poly(A)+ mRNA was isolated from normal human brain and from the brain (frontal cortex) of a patient diagnosed with CJD. The expression of ScRG-1 mRNA was examined by Northern blot analysis using human ScRG-1 cDNA as a probe (Fig. 2A). ScRG-1 mRNA was found to be 3-fold more abundant in the brain of a patient with CJD than in the brain of a normal individual. In contrast, beta -actin mRNA levels were similar in both samples (Fig. 2A). As expected an increased expression of GFAP transcripts was also detected in the CJD mRNA, indicating that a glial reaction had occurred in the brain tissue examined (Fig. 2A), and the presence of proteinase K-resistant PrP was also clearly detected in this sample (data not shown). Although these results are highly suggestive, only two individuals have been compared and any definitive conclusion concerning the expression of the ScRG-1 gene will have to await more extensive studies, particularly those employing the techniques of in situ hybridization and/or immunocytochemistry in addition to Northern blot analysis. It is quite possible that the increased expression observed results from the activation of a particular subset of cells in the brain. Thus, the increase in ScRG-1 mRNA detected using Northern blot analysis may underestimate an increased expression in a particular cell population, because all brain cells contribute to the mRNA analyzed by this method. Interestingly, the level of cathepsin S transcripts was also found to be higher in the CJD RNA sample examined (Fig. 2A) in agreement with the 3-8-fold increase in the cathepsin S mRNA, which has been reported in scrapie-infected mouse brain (2). The gliosis that precedes the spongiosis and neuronal death in TSE consists of both an astrocytosis and a microglial activation. The increased expression of ScRG-1 and cathepsin S transcripts that we observed in CJD brain tissue may result from this double cellular activation. In Alzeihmer's disease an increased expression of cathepsin S has been reported to reflect the activation of microglial cells (11).

The laminin receptor, which has recently been shown to interact with PrP, may constitute a receptor for this protein (12). The laminin receptor is increased 2-fold in extracts of brain from scrapie-infected mice (12), indicating that even a modest increase in the level of expression of a gene may be of considerable biological importance in such disorders.

Tissue Distribution and Developmental Expression of Human ScRG-1 mRNA-- Although mouse ScRG-1 mRNA was found to be expressed preferentially in brain tissue (2), the expressed sequence tags related to ScRG-1 and used to define primers to isolate the human cDNA (see above) were recovered from various tissues including brain, testis, aorta, and pregnant uterus. It was of interest therefore to determine the specificity of expression of the gene in different tissues, using a membrane to which poly(A)+ RNA from 50 human tissues have been immobilized in separate dots (Fig. 3). ScRG-1 is abundantly expressed in the central nervous system of the adult, in all the areas of brain investigated, and in spinal cord but is poorly or not expressed at all in fetal brain, indicating marked developmental regulation of the gene. A high level of ScRG-1 transcripts was also observed in testis and aorta, organs with low specificity of expression, which is in agreement with the report of expressed sequence tags from these tissues. We also analyzed, by Northern blotting, mRNA from various human tissues, heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas for the presence of ScRG-1 mRNA (Fig. 2C). The ScRG-1 message was highly expressed in the brain as expected and also to a 6-fold lesser extent in the heart. A faint signal was also detected upon overexposure of the blot in almost all the organs examined, indicating that the low level of hybridization observed in most of the human organs and shown in Fig. 3 corresponds to a real albeit low level of expression (data not shown).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Tissue distribution of the human ScRG-1 mRNA. A membrane to which poly(A)+ RNA from 50 human tissues had been immobilized in separate dots was hybridized with the human ScRG-1 cDNA according to the instructions of the supplier, and the membrane was subjected to PhosphorImager quantification. A1-A8: whole brain, amygdala, caudate nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus, and medulla oblongata. B1-B7, occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, subthalamic nucleus, and spinal cord. C1-C8, heart, aorta, skeletal muscle, colon, bladder, uterus, prostate, and stomach. D1-D8, testis, ovary, pancreas, pituitary gland, adrenal gland, thyroid gland, salivary gland, and mammary gland. E1-E8, kidney, liver, small intestine, spleen, thymus, peripheral leukocyte, lymph node, and bone marrow. F1-F4, appendix, lung, trachea, and placenta. G1-G7, fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, and fetal lung. Most of the tissues are pools of several individuals except for the cerebral cortex and adult liver. The fetal mRNA are pools from at least 14 embryos of ages between 17 and 25 weeks. The mRNA samples dotted on the membrane have been normalized to the mRNA expression level of eight different housekeeping genes.

Conclusions-- The increased level of expression of ScRG-1 transcripts in scrapie-infected mouse brain (2) and probably also in the brain of CJD-infected individuals suggests that ScRG-1 may be involved in the neurodegenerative process in TSE. Indeed, the ScRG-1 protein may play an important physiological role in the central nervous system, as indicated by the high degree of conservation of its amino acid sequence in both man and mouse, the presence of a cleavable signal peptide indicating that the ScRG-1 protein is secreted outside the cell, and its high level of expression in the central nervous system. The potential importance of the gene is also emphasized by the observation that its expression is under developmental regulation.

    FOOTNOTES

* This work was supported by grants from CNRS (Programme de Recherche sur les Encéphalopathies Spongiformes Sub-aigües Transmissibles et les Prions, Action Concertée Coordonnée Number 2), from INSERM, and from the Association Nouvelles Recherches Biomédicales.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AJ223206 and AJ224677.

§ Recipient of a fellowship from the Association Recherche et Partage (Paris, France).

Dagger Dagger To whom correspondence should be addressed: Lab. of Viral Oncology, 7 rue Guy Moquet, BP8, 94801 Villejuif, France. Tel.: 33-1-49-58-34-22; Fax: 33-1-49-58-34-44; E-mail: mdron{at}infobiogen.fr.

1 The abbreviations used are: TSE, transmissible spongiform encephalopathies; CJD, Creutzfeldt-Jakob disease; PrP, prion protein; RACE, rapid amplification of cDNA ends; ORF, open reading frame; kb, kilobase(s); contig, group of overlapping clones; bp, base pair(s).

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Prusiner, S. B. (1997) Science 278, 245-251[Abstract/Free Full Text]
  2. Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.-P., Lasmézas, C., Dormont, D., Tovey, M. G., and Dron, M. (1998) J. Biol. Chem. 273, 7691-7697[Abstract/Free Full Text]
  3. Gomi, H., Yokoyama, T., Fujimoto, K., Ikeda, T., Katoh, A., Itoh, T., and Itohara, S. (1995) Neuron 14, 29-41[Medline] [Order article via Infotrieve]
  4. Brown, D. R., Schmidt, B., and Kretzschmar, H. A. (1996) Nature 380, 345-347[CrossRef][Medline] [Order article via Infotrieve]
  5. Williams, A., Van Dam, A. M., Ritchie, D., Eikelenboom, P., and Fraser, H. (1997) Brain Res. 754, 171-180[CrossRef][Medline] [Order article via Infotrieve]
  6. Raeber, A. J., Race, R. E., Brander, S., Priola, S. A., Sailer, A., Bessen, R. A., Mucke, L., Manson, J., Aguzzi, A., Oldstone, M. B. A., Weissmann, C., and Chesebro, B. (1997) EMBO J. 16, 6057-6065[Abstract/Free Full Text]
  7. Duguid, J., and Trzepacz, C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 114-117[Abstract]
  8. Campbell, I. L., Eddleston, M., Kemper, P., Oldstone, M. B. A., and Hobbs, M. V. (1994) J. Virol. 68, 2383-2387[Abstract]
  9. Diedrich, J. F., Minnigan, H., Carp, R. I., Whitaker, J. N., Race, R., Frey, W., II, and Haase, A. T. (1991) J. Virol. 65, 4759-4768[Medline] [Order article via Infotrieve]
  10. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299[Medline] [Order article via Infotrieve]
  11. Lemere, C. A., Munger, J. S., Shi, G. P., Natkin, L., Haass, C., Chapman, H. A., and Selkoe, D. J. (1995) Am. J. Pathol. 146, 848-860[Abstract]
  12. Rigier, R., Edenhoffer, F., Lasmezas, C. I., and Weiss, S. (1997) Nat. Med. 3, 1383-1388[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Dron, M.
Articles by Tovey, M. G.
Articles citing this Article
PubMed
PubMed Citation
Articles by Dron, M.
Articles by Tovey, M. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.